Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

被引:0
|
作者
Harrison, Simon [1 ,2 ]
Riley, Caroline Hasselbalch [3 ]
Manier, Salomon [4 ]
Yoon, Sung-Soo [5 ]
Pinto, Antonio [6 ]
Cazaubiel, Titouan [7 ]
Guidetti, Anna [8 ]
Popat, Rakesh [9 ]
Touzeau, Cyrille [10 ]
Ocio, Enrique [11 ]
Offner, Fritz [12 ]
Rodriguez-Otero, Paula [13 ]
Rizzello, Ilaria [14 ,15 ]
Mateos, Maria-Victoria [16 ]
Broeske, Ann-Marie [17 ]
Dekhtiarenko, Iryna [18 ]
Dimier, Natalie [19 ]
Eckmann, Jan [17 ,18 ]
Helms, Hans-Joachin [20 ]
Jacob, Wolfgang [17 ]
Schneider, Meike [20 ]
Sleiman, Nassim [20 ]
Weisser, Martin [17 ]
Carlo-Stella, Carmelo [21 ,22 ]
机构
[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Royal Melbourne Hosp, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Rigshospitalet, Copenhagen, Denmark
[4] CHU Lille, Lille, France
[5] Seoul Natl Univ, Coll Med, Seoul, South Korea
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[7] CHU Bordeaux, Bordeaux, France
[8] Ist Nazl Tumori, Milan, Italy
[9] NHS Univ Coll London Hosp, London, England
[10] CHU Nantes, Nantes, France
[11] Marques Valdecilla Univ Hosp, Santander, Spain
[12] Univ Ziekenhuis Gent, Ghent, Belgium
[13] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[14] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedo, Bologna, Italy
[15] Univ Bologna, Bologna, Italy
[16] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain
[17] Roche Innovat Ctr Munich, Penzberg, Germany
[18] Roche Innovat Ctr Zurich, Zurich, Switzerland
[19] Roche Innovat Ctr Welwyn, Welwyn Garden City, England
[20] Roche Innovat Ctr Basel, Basel, Switzerland
[21] Humanitas Univ, Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy
[22] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OA-05
引用
收藏
页码:S3 / S4
页数:2
相关论文
共 50 条
  • [31] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [32] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [33] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [35] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial
    D'Souza, Anita
    Rodriguez-Valdes, Cesar
    Kumar, Shaji
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Weisel, Katja
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando
    Rosenberg, Tanya
    Pothacamury, Rajvineeth
    Polepally, Akshanth
    Ahsan, Aarif
    Lee, Shane
    Jin, Ziyi
    Spence, Shelli
    Talati, Chetasi
    McKay, John
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48
  • [36] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
    Mancia, Stefania Stefania
    Farrell, Annamaria
    Louw, Karen
    Florendo, Erika
    Aronson, Elizabeth
    Purcell, Kiah
    Catamero, Donna D.
    Escalon, Juliet
    Thomas, Joanne
    Aponte, Annel
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2021, 138
  • [37] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
    Nooka, Ajay K.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Oriol Rocafiguera, Albert
    Chari, Ajai
    Karlin, Lionel
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez, Joaquin
    Sidana, Surbhi
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Stephenson, Tara
    Banerjee, Arnob
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)xCD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study
    Van De Donk, Niels W. C. J.
    Krishnan, Amrita
    Oriol, A.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Costa, Luciano
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi
    Russell, Jeffery
    Goldberg, Jenna
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S16 - S17
  • [39] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander M.
    Levy, Moshe Y.
    Dalovisio, Andrew P.
    Bahlis, Nizar J.
    Solh, Melhem
    Sebag, Michael
    Jakubowiak, Andrzej
    Jethava, Yogesh S.
    Costello, Caitlin L.
    Chu, Michael P.
    Savona, Michael R.
    Gasparetto, Cristina
    Trudel, Suzanne
    Chou, Jeffrey
    Udata, Chandrasekhar
    Basu, Cynthia
    Krupka, Heike I.
    Raje, Noopur S.
    BLOOD, 2020, 136
  • [40] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
    Cortes-Selva, Diana
    Casneuf, Tineke
    Vishwamitra, Deeksha
    Stein, Sarah
    Perova, Tatiana
    Skerget, Sheri
    Ramos, Elena
    van Steenbergen, Laure
    De Maeyer, Dries
    Boominathan, Rengasamy
    Lau, Onsay
    Davis, Cuc
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa M.
    Kobos, Rachel
    Goldberg, Jenna D.
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad
    Bahlis, Nizar Jacques
    Van de Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2022, 140